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A pharmacokinetically guided phase I study of topotecan and etoposide phosphate was conducted in recurrent ovarian cancer. The
scheduling of the topoisomerase I and II inhibitors was determined using in vitro activity data. All patients had recurrent disease
following prior platinum-containing chemotherapy. Patients had a World Health Organisation performance status of 0–2 and
adequate bone marrow, renal and hepatic function. Treatment was with topotecan intravenously for 5 days followed immediately by
a 5-day intravenous infusion of etoposide phosphate (EP), with pharmacokinetically guided dose adjustment. Plasma etoposide levels
were measured on days 2 and 4 of the infusion. A total of 21 patients entered the study. In all, 48% were platinum resistant and 71%
had received prior paclitaxel. The main toxicities were haematological, short lived and reversible. A total of 29% of patients
experienced grade 4 thrombocytopenia and 66% grade 4 neutropenia after the first cycle. Neutropenia and thrombocytopenia was
dose limiting. The maximum-tolerated dose was topotecan 0.85mgm
 2day
 1 days 1–5 followed immediately by a 5-day infusion of
EP at a plasma concentration of 1mgml
 1. The response rate (RR) was 28% in 18 evaluable patients. There was marked interpatient
variability in topoisomerase IIa levels measured from peripheral lymphocytes, with no observed increase following topotecan. This
regimen of topotecan followed by EP demonstrated good activity in recurrent ovarian cancer and was noncrossresistant with
paclitaxel. Both the toxicity and RR was higher than would be expected from the single agent data, in keeping with synergy of action.
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Advanced ovarian carcinoma is usually sensitive to chemotherapy
with durable complete remissions but relapse often occurs,
necessitating further treatment. Evaluation of appropriate active
regimens for patients with recurrent or resistant ovarian cancer
allows the possibility of eventually incorporating them into initial
management (Stuart, 2003). The initial treatment for advanced
ovarian cancer comprises cytoreductive surgery followed by
platinum-containing chemotherapy with or without paclitaxel
(McGuire et al, 1996; Muggia et al, 2000; Piccart et al, 2000; ICON3
collaborators, 2002). Effective noncrossresistant second- and third-
line therapies are required. This study evaluates the sequential
combination of topotecan and etoposide phosphate (EP).
Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals,
Philadelphia, PA, USA) is a semisynthetic analogue of the plant
alkaloid camptothecin which is a topoisomerase I inhibitor and
is active in ovarian cancer. According to phase I trials, the best
schedule and maximum-tolerated dose (MTD) of topotecan is
1.5mgm
 2day
 1 for 5 consecutive days in a 21-day cycle
(Rowinsky and Verweij, 1997). In phase I studies of topotecan,
the main dose-limiting side effect was neutropenia, which was
predictable, of short duration and noncumulative. Other side effects
included thrombocytopenia, alopecia and gastrointestinal toxicity.
Mucositis, fatigue, rashes and abnormalities of liver function were
also rarely reported. Phase II studies have shown activity and
prolonged disease stabilisation in patients with recurrent ovarian
cancer (Creemers et al, 1996; Kudelka et al, 1996). This was also
observed in patients whose disease had progressed following
prior chemotherapy with paclitaxel or platinum agents (Bookman
et al, 1998; Gore et al, 2001). A randomised phase III study that
compared topotecan to paclitaxel as second-line therapy after
platinum-containing regimens showed a higher response rate
(20.5 vs 13.2%, P¼0.138), longer response duration (32 vs 20
weeks, P¼0.222) and longer time to progression (23 vs 14 weeks,
P¼0.002) for topotecan, although there was no significant
improvement in survival (ten Bokkel Huinink et al, 1997). In view
of these studies, topotecan has been licensed as a second-line
therapeutic agent for ovarian cancer. More recently, a shorter 3-day
infusion of topotecan 1.5mgm
 2day
 1 in advanced ovarian cancer
has shown similar activity but was less toxic than standard
treatment (Markman et al, 2000).
Etoposide, a topoisomerase II inhibitor, has antitumour activity
in a wide range of tumours including small-cell lung cancer
(SCLC), germ cell tumours of the testis and lymphomas. Etoposide
has been given in a variety of schedules both as a single agent and
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sin combination therapy in a number of tumour types (Hande,
1998). Response to etoposide is dependent on drug scheduling as
its activity is specific to S-phase of the cell cycle (Joel et al, 1998).
Oral etoposide has been investigated as a route of prolonged
administration (Hainsworth et al, 1989). Although oral schedules
maintain low plasma etoposide levels throughout the treatment
period, plasma concentrations still vary between peak and
pretreatment levels. Additionally, the absorption of oral etoposide
is incomplete (60% bioavailability) and variable, both between and
within patients (Harvey et al, 1985b; Slevin and Joel, 1993). Phase
II studies with oral etoposide showed response rates of 24 and 26%
in patients with relapsed or platinum-resistant ovarian cancer
(Hoskins and Swenerton, 1994; Seymour et al, 1994). Myelotoxicity
was dose limiting in both studies. A third phase II study showed
response rates of 34.1% in platinum-sensitive patients and 26.8%
in platinum-resistant patients. Almost one-third of platinum-
resistant responders had also received paclitaxel (Rose et al, 1998).
The main toxicities were haematological. Thus, oral etoposide is
noncrossresistant with both platinum agents and paclitaxel.
EP (Etopophos, Bristol Myers Squibb Co, Princeton, NJ, USA) is
rapidly converted to etoposide in the blood. It is approximately 20
times more soluble than etoposide and can therefore be given as a
prolonged outpatient infusion. A recent phase II study has
evaluated the efficacy of EP in patients with relapsed or resistant
ovarian carcinoma, previously treated with both carboplatin and
paclitaxel (O’Byrne et al, 1997). To ensure that target concentra-
tions were achieved rapidly, a loading dose of EP was given
intravenously over 30min. At the same time, a constant infusion of
EP was commenced to maintain plateau levels at the target
concentration. Plasma drug monitoring was performed 24h into
the infusion and at 3 days, with infusion rate modification if
necessary to ensure that target levels were achieved. In the first
cohort of 16 patients treated with EP to achieve a plasma level of
2mgml
 1, no objective responses were observed although disease
stabilisation occurred in four patients. The next cohort of patients
were treated at 3mgml
 1. Of 28 patients, 26 were evaluable and
the response rates were 43% for platinum-sensitive patients and
17% for platinum-resistant patients. In all, 20% of patients in the
second cohort experienced grade 4 myelosuppression, suggesting
that in heavily pretreated patients with ovarian cancer, the single
agent dose of EP is 3mgml
 1 infused for 5 days.
There are theoretical reasons and some preclinical data to
suggest that topotecan and etoposide may act synergistically in
sequential combination with the schedule of administration being
important (Whitacre et al, 1997). A proposed mechanism for
synergy is that topoisomerase I inhibitors increase topoisomerase
IIa levels, sensitising malignant cells to the effects of topoisome-
rase II inhibition (Whitacre et al, 1997). Thus, the sequential
administration of topotecan followed by EP might lead to total
topoisomerase ‘shutdown’ and synergistic antitumour activity.
This study assesses the combination of a 5-day schedule of
topotecan followed closely by a continuous 5-day infusion of EP
for toxicity and to identify the MTD of both drugs, in patients with
recurrent or platinum-resistant ovarian carcinoma. In addition,
the combination of both drugs was studied in vitro to evaluate the
schedule and potential synergy.
PATIENTS AND METHODS
Eligibility
The study was open to patients with histologically confirmed
epithelial ovarian carcinoma, primary serous papillary peritoneal
carcinoma or fallopian tube carcinoma and evaluable, relapsed or
platinum-resistant disease. Platinum-resistant disease was defined
as progression on treatment or relapse within 6 months of
completion of initial treatment. Patients were required to be over
18 years old and with a World Health Organisation (WHO)
performance status of 0–2. They were required to have
adequate bone marrow (neutrophils X1.5 10
9l
 1, platelets
X100 10
9l
 1), renal (normal serum creatinine and EDTA
clearance 440mlmin
 1) and hepatic function (serum bilirubin
o50mmoll
 1, albumin 430gl
 1, aspartate amino transferase and
alkaline phosphatase p3 times the upper limit of normal or p5
times the upper limit of normal in the presence of liver
metastases). All patients had recovered from the acute toxic effects
of previous treatment and had not received radiotherapy,
chemotherapy or immunotherapy within 4 weeks of trial entry.
Pregnant women, nursing mothers and patients not using adequate
contraception were excluded, as were patients with clinical
evidence of cerebral metastases. All patients gave written informed
consent for the trial and for insertion of a Hickman line to allow
drug delivery. The trial was approved by the local research ethics
committee and was conducted according to the recommendations
of the Declaration of Helsinki, Hong Kong Amendment 1989 and
the ABPI guidelines for good clinical practice.
Study design
This single centre phase I study used a modified Fibonacci design
with a planned minimum of three patients at each dose level. As
both chemotherapy agents in this study are myelotoxic, topotecan
was given at 1.0mgm
 2day
 1 consecutively for days 1–5, two-
third of its usual recommended dose. This was followed by a
continuous infusion of EP, achieving a plasma concentration of
etoposide of 2mgml
 1 for days 6–10 in dose level 1a and adjusted
thereafter according to toxicity. Dose levels used in this study are
listed in Table 1. This starting dose was chosen following a phase II
study of EP alone (O’Byrne et al, 1997), in which a dose level of
2mgml
 1 for 5 days was well tolerated. Patients were retreated in
four weekly cycles. Standard antiemetic cover was with metoclo-
pramide, as required. Dexamethasone and tropisetron were used if
patients had persistent nausea. Patients were also routinely given
warfarin 1mg once daily as prophylaxis against Hickman line-
induced venous thrombosis. Granulocyte colony-stimulating factor
was not given in this study.
Dose escalation to higher levels was planned providing that no
patient in the cohort experienced dose-limiting toxicity (DLT). If
however, two out of three or three out of six patients in a single
dose level experienced DLT, then it was planned to stop recruiting
at that level and to include additional patients at a lower dose level.
As it was anticipated that myelotoxicity might be dose limiting
even at dose level 1a, further (lower) dose escalation schemes were
devised. As patients who have received both paclitaxel and
carboplatin in the past may have less marrow reserve than patients
who have only received carboplatin, it was planned to expand the
MTD level to include at least four patients who had previously
been treated with both agents.
Dose-limiting toxicity was defined using the CALBG (Cancer
and Leukemia Group B) common toxicity grading, as grade 4
haematological toxicity during the first cycle of treatment (grade 4
thrombocytopenia or grade 4 neutropenia lasting for more than 5
days or complicated by fever), or grade 3 nonhaematological
Table 1 Topotecan and etoposide dose levels
Dose level Topotecan (mgm
 2day
 1) Etoposide level (lgml
 1)
1a 1.0 2.0
1b 0.85 2.0
2a 0.85 1.0
2b 0.85 1.5
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stoxicity (excluding nausea, vomiting and alopecia) or grade 4
vomiting in patients with maximal antiemetic supportive care. As
it was probable that myelotoxicity would be cumulative, only first
cycle effects were defined as contributing to DLT. The stop dose
was defined as the dose at which two out of three or three out of six
patients experienced DLT. Maximum-tolerated dose was defined as
the highest dose level at which no more than one out of six patients
experienced DLT. The MTD is therefore the dose below the stop
dose level.
In the 2 weeks prior to recruitment into the study, patients were
assessed by clinical examination and with a chest radiograph,
EDTA (ethylene diamine tetra-acetic acid) clearance, full blood
count and differential, serum electrolytes, including calcium and
phosphate, creatinine and urea, liver function tests, Ca125 and
urinalysis. Within 4 weeks of recruitment, all patients had full
assessment of any measurable/evaluable lesions by CT scan of
abdomen and pelvis and by other investigations such as clinical
photography, CT thorax, MRI or bone scans as clinically indicated.
Blood tests and urinalysis were repeated on the day prior to
starting treatment, before each subsequent cycle and 2 weeks after
completing the study. Dose reductions to the next lowest dose level
were made if patients experienced any grade 4 haematological or
grade 3 nonhaematological toxicity (excluding alopecia). Treat-
ment in subsequent cycles was delayed until the toxicity had
resolved. Quality of life (QOL) was assessed with the EORTC
(European Organisation for Research and Treatment of Cancer) 30
questionnaire prior to cycles 1, 3 and 6.
Patients, who tolerated the chemotherapy and had stable or
responding disease after three cycles, were continued on study for
a maximum of six cycles. If there was evidence of progressive
disease, then treatment was stopped after a minimum of two
cycles. The response to treatment was formally assessed after three
and six cycles. Disease response was assessed according to World
Health Organisation (WHO) criteria. The duration of response was
calculated as the period from the final course of chemotherapy
through to the date of confirmed relapse.
Drug formulation and administration
Topotecan was reconstituted in sterile saline and given as an
infusion via a Hickman line over 30min, on days 1–5 of each
cycle. Bristol-Myers Squibb Pharmaceuticals supplied EP, as
113.6mg of lyophilised powder in a sterile glass vial. Each vial
was reconstituted with sterile saline. Starting on day 6, EP was
infused via a Hickman line, starting with a loading dose of
10 target etoposide level mgm
 2, given over 30min, followed
by a 5-day continuous infusion in mgm
 2h
 1. The initial infusion
rate was calculated and adjusted according to measured plasma
etoposide concentrations (Joel et al, 1996).
Therapeutic drug monitoring
Etopside phosphate was commenced on the afternoon of day 6. On
the morning of day 7 (18h after the start of the infusion) and on
day 9 of each cycle, peripheral venous blood samples were drawn
for determination of total plasma etoposide levels, as described
previously (Harvey et al, 1985a; Joel et al, 1996, 1998). Plasma
standards covering the range 0.5–5.0mgml
 1 were used; patient
samples were run in duplicate, with quality control samples at two
concentrations (1.25 and 3.5mgml
 1). Between-assay reproduci-
bility based on these quality control samples was o10%. Plasma
etoposide concentration was obtained on the day of sampling, with
a typical turn-around time of 3–4h to permit adjustment of the
infusion rate on that day. Dose modifications were made according
to the measured steady-state plasma etoposide concentration using
the following formula: (Joel et al, 1996)
NewcontinuousinfusionðCIÞdoseðmgh
 1Þ¼
CurrentCIðmgh
 1Þ 
Targetplasmaconcentration
Measuredplasmaconcentration
Adjustments to the infusion rate were only made if the measured
plasma etoposide concentration differed by 410% from the target
concentration. The initial infusion rates for cycles 2–6 were based
on the plasma etoposide concentration from the preceding cycle.
Preclinical evaluation of cell lines
Ovarian cancer cell lines (A2780, SKOV-3 and OVCAR-3) were
cultured in RPMI 1640 medium supplemented with 10% foetal
bovine serum, penicillin 100Uml
 1 and streptomycin 100mgml
 1
(Gibco BRL, Paisley, UK). Cells were incubated at 371Ci na
humidified atmosphere containing 5% CO2. Stock solutions of the
topoisomerase I inhibitor, SN-38 (gift from Aventis Pharma,
France) were prepared in DMSO (dimethylsulphoxide, Sigma,
Dorset, UK), and etoposide (Sigma) in 50% methanol. These were
diluted to the appropriate concentrations in media immediately
prior to use. The final concentration of DMSO in the culture
medium was o0.02%. Cells were plated at a density of 2 10
5ml
 1
and allowed to attach for 24h prior to drug treatment. The activity
of SN-38 and etoposide as single agents was first determined across
a range of concentrations (0–100ngml
 1 SN-38, 0–10mM etopo-
side). The concentration of each drug resulting in 10% apoptosis
after 3 days was determined from concentration effect curves using
a sigmoidal EMAX model and used in subsequent combination
experiments. These concentrations were 3.125ngml
 1 for SN-38 in
each cell line, 2mM etoposide in A2780, 1mM etoposide in OVCAR-3
and 3mM etoposide in SKOV3. Drug medium was replaced every
24h, with detached cells harvested by centrifugation and
resuspended in the fresh drug medium.
Cell cycle distribution, including the apoptotic (sub-G0/G1)
population, was determined using propidium iodide following the
controlled extraction of low molecular weight DNA. Cells were
harvested by trypsinisation and centrifugation, and fixed in 70%
ethanol overnight. After removal of fixative, cells were resus-
pended in 750ml of DNA extraction buffer (96% 0.2 M Na2HPO4,
4% 0.1 M citric acid) for 5min at room temperature. Buffer was
removed by centrifugation and the cells were resuspended in DNA
staining solution (50mgml
 1 propidium iodide and 50mgml
 1
ribonuclease A, Sigma) for 1h in the dark. Fluorescence data from
10000 cells was collected on a FACScan flow cytometer (Becton
Dickinson) and analysed using LYSYS II software. Results
presented are the mean of a minimum of three separate
experiments. Statistical comparisons were made using a paired
t-test.
Peripheral blood topoisomerase IIa levels
In all, 10ml blood samples were taken into iced cold EDTA
containers on days 1, 6 and 10 of cycle one for topoisomerase IIa
analysis. Samples were processed immediately; 5ml of blood was
layered onto 5ml lymphoprep (Nycomed Pharma AS Diagnostics,
Oslo, Norway) and centrifuged for 20min at 41C. The lymphocyte
layer was washed once with phosphate-buffered saline and
recentrifuged. The cell pellet was resuspended in 2  SDS sample
buffer and incubated at 901C for 10min before freezing at  701C.
Polyacrylamide gel electrophoresis and Western blotting was
performed as previously described (Ausubel et al, 1994). Blots
were probed with a monoclonal anti-topoisomerase IIa antibody,
1F6 (Negri et al, 1992). b-Tubulin (monoclonal anti-b-tubulin
clone 2.1, Sigma, Missouri, USA) was used as a loading control.
Autoradiographs were scanned and the band intensity of the lanes
compared using FluorChem software, with the tubulin band as a
control for each sample.
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sRESULTS
Patients and treatment
A total of 21 patients were entered into this study (Table 2). One
patient’s performance status fell from 2 when she was consented
for the trial to 3 on day 1 of the study. All patients had received
previous platinum-containing chemotherapy and 15 out of 21
(71%) had also received paclitaxel (Table 3a). Only two patients
(10%) progressed through first-line platinum-containing chemo-
therapy. A total of 10 patients (48%) either progressed following
first-line chemotherapy or had duration of response of less than
6 months and were therefore classified as platinum-resistant
(Table 3a). A total of 15 patients had received two or more
chemotherapy regimens (Table 3b). One patient had had prior
exposure to etoposide, given orally as third-line chemotherapy.
In this study, a total of 100 cycles of trial chemotherapy were
given with a mean of 4.8 cycles per patient. A total of 12 patients
completed all six planned cycles of chemotherapy.
Toxicity
The main toxicity was myelosuppression (Table 4). Both patients
entered at dose level 1a (T-1.0/E-2.0) experienced grade 4
neutropenia with associated sepsis following the first cycle of
treatment and therefore the next patient was recruited to the lower
dose level of 1b (T-0.85/E-2.0). This dose level also proved to be
excessively myelotoxic, with all three patients suffering grade 4
neutropenia, two with associated sepsis. Dose level 2a (T-0.85/E-1.0)
was better tolerated and was therefore expanded to 11 patients in
order to allow for better assessment of toxicity at this dose level.
Four of these patients experienced grade 4 neutropenia, however
this was for fewer than 5 days and was complicated by sepsis in
only one case. As DLT at dose level 2a was observed in only one of
11 patients, a higher dose level, 2b (T-0.85/E-1.5) was given to a
further five patients. Dose-limiting toxicity was also seen at this
dose level, with grade 4 neutropenia complicated by sepsis in four
out of five patients. Of 13 patients with grade 4 neutropenia during
cycle 1, 10 became septic. This high incidence of neutropenic
sepsis may reflect the heavy pretreatment of this patient group and
the fact that neither prophylactic antibiotics nor G-CSF were given
in this trial. There were no deaths from neutropenic sepsis. Of
note, the haematological toxicity in this study was of short
duration with only three out of 21 patients having a treatment
delay of X1 week at cycle 2. Nonhaematological toxicity was not
dose limiting, detailed in Table 4. Generally this was mild and
manageable with grade 3 toxicities of nausea, stomatitis and
diarrhoea seen in three, one and one patients, respectively.
Pharmacokinetics
All patients had pharmacokinetic sampling during each treatment
cycle, with adjustment of the infusion rate to achieve the targeted
plasma etoposide level. The starting infusion rate for cycle 1 did not
allow for differences in renal function, as the total etoposide plasma
clearance correlated only poorly with the EDTA creatinine clearance
(Figure 1). The starting infusion rate for cycle 2 and subsequent cycles
was the same as the final infusion rate from the preceding cycle.
There was considerable interpatient variability in the measured
plasma etoposide levels (Figure 2). Across all cycles, samples from
day 2 showed that 32% of patients had measured plasma etoposide
levels within 10% of the target level. This improved to a mean of
58% for day 4 measurements. Measured etoposide levels were
within 20% of the target level for 66% of patients on day 1 and 85%
by day 4. Patients with measured etoposide levels more or less than
10% from the target level had their etoposide phosphate infusion
adjusted. Table 5 details the number of patients for each cycle for
whom this was necessary.
Tumour responses at the end of treatment
A total of 18 patients were evaluable for tumour response, having
completed at least three cycles of treatment. Objective tumour
Table 2 Patient details
Age and PS Histology Stage at presentation Previous surgery
Number of patients, n 21 Ovary – serous 12 Stage I 0 TAH, BSO and omentectomy 9
Age – mean 54 Ovary – endometroid 4 Stage II 1 BSO and TAH 3
Age – range 31–66 Ovary – clear cell 1 Stage III 14 BSO 4
PS¼0 6 Ovary – mucinous 1 Stage IV 6 BSO and omentectomy 2
PS¼1 11 Primary peritoneal – serous 1 RSO and omentectomy 1
PS¼2 3 Primary peritoneal – clear cell 1 Biopsy only 2
PS¼3 1 Fallopian tube – endometroid 1
TAH¼total abdominal hysterectomy; BSO¼bilateral salpingo-oophorectormy.
Table 3a Previous treatment – first-line chemotherapy
Carboplatin
Carboplatin+
paclitaxel
Cisplatin-
containing
regimens
Number of patients 12 7 2
C R 542
P R 330
S D 200
P D 200
Platinum sensitive 7/12 3/7 1/2
Mean duration of first
remission (min) (excluding
patients with PD)
18.0 6.3 9.0
CR¼complete remission; PR¼partial remission; SD¼stable disease; PD¼pro-
gressive disease.
Table 3b Previous treatment – second- and third-line chemotherapy
Second-line
chemotherapy
Third-line
chemotherapy
Treatment Total CR PR SD PD Total CR PR SDPD
Carboplatin 3 1 1 1
Paclitaxel 4 2 1 1 2 1 1
Carboplatin+paclitaxel 2 2
CAP 2 2
FEC 1 1
Cyclophosphamide+epirubicin 1 1
Oral etoposide 1 1
Noncytotoxic – trial treatment 2 1 1 1 1
CR¼complete remission; PR¼partial remission; SD¼stable disease; PD¼pro-
gressive disease.
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sresponses were demonstrated in 28% (five out of 18) of patients at
completion of treatment (Table 6). All responding patients had
been sensitive to platinum first line and four out of five had also
been treated previously with paclitaxel. All of the 18 evaluable
patients had an elevated Ca125 level at the start of the trial. Six
patients had a X50% fall in their level, and in a further five
patients the Ca125 levels fell below baseline but by less than 50%
after six cycles. Of the 21 patients, 11 went onto between 1 and 3
(mean 1.5) further regimens of chemotherapy, after completion of
chemotherapy in this study. The median survival for patients was
11.7 months from the start of treatment on this study, with all
patients having died at the time of this report.
Quality of life
Quality of life was measured during the treatment using the
EORTC QL-30 questionnaire (Figure 3). Quality of life was
statistically related to patients’ haemoglobin level and to their
level of symptoms. There was a trend for QOL to improve during
the trial; however, the difference was not statistically significant.
Preclinical studies
Apoptosis was assessed following exposure to etoposide and SN-38
in combination (Figure 4A–C). With the exception of SN-38 in
A2780 cells, where the response was mainly cell cycle arrest even
up to 100ngml
 1, SN-38 drug concentrations used were those that
resulted in approximately 10% apoptosis after a 3-day exposure.
The percentage of apoptotic cells in each experiment was
determined by flow cytometry using propidium iodide staining
of DNA on the last day of each treatment.
For each cell line, exposure to both drugs simultaneously
resulted in less apoptosis than would be expected from the additive
effect of each drug given separately. Schedules in which the agents
were used consecutively were consistently more active than those
involving concurrent exposure, even though the overall exposure
(concentration time) for both agents was the same in each
schedule. The most active combination overall, as evaluated by
induction of apoptosis, was SN-38 for 3 days, followed by 1 day
drug free and then etoposide for a further 3 days in all cell lines
(Figure 4A–C).
Table 4 Toxicity data
Dose-limiting toxicity (following cycle 1 only)
Dose level Number of patients (n) Thrombocytopenia Neutropenia Sepsis
1a (1.0/2.0) 2 1 2 2
1b (0.85/2.0) 3 1 3 3
2a (0.85/1.0) 11 0 4 1
2b (0.85/1.5) 5 4 4 4
Haematological toxicity over 6 cycles
Dose level n Anaemia Thrombocytopenia Neutropenia Sepsis
1a (1.0/2.0) 2 0 1 2 2
1b (0.85/2.0) 3 0 2 3 3
2a (0.85/1.0) 11 2 3 6 5
2b (0.85/1.5) 5 0 4 5 4
Nonhaematological toxicity over 6 cycles
Dose level n Alopecia grade p2 Nausea grade¼3 Stomatitis grades 2–3 Diarrhoea grades 2–3
1a (1.0/2.0) 2 2 0 2 1
1b (0.85/2.0) 3 2 1 2 1
2a (0.85/1.0) 11 11 2 2 0
2b (0.85/1.5) 5 5 0 1 0
Only grade 4 haematological toxicity presented.
y = 0.133x + 17.515
R
2 = 0.2537
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Figure 1 Etoposide clearance. Relationship between etoposide clear-
ance and EDTA clearance (renal function) prior to treatment, shown as a
regression curve (A) and as a scatter graph for EDTA clearance below and
above 60mlmin
 1 (B).
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sTopoisomerase IIa levels
The topoisomerase IIa levels were not increased in peripheral
lymphocytes after topotecan treatment (Figure 5). The topoisome-
rase IIa levels in 10 patients showed a mean reduction of 2.14
arbitrary units (P¼0.02) following topotecan, compared to
baseline measurements. However, there was no trend for change
overall with treatment for all patients or for the subset of those
who responded to treatment.
DISCUSSION
One of the goals of combination chemotherapy is the development
of regimens with synergistic activity and noncrossover toxicity.
This paper explores the combination of topotecan and EP; from
preclinical studies to suggest the most active sequencing of the
drugs, through to a phase I study of the combination in patients
with advanced ovarian cancer.
Release of tortional stress in supercoiled DNA is necessary prior
to replication and cell division. Topoisomerase I induces a single-
strand break in DNA, allowing it to unwind, before repair of the
break. Topotecan binds and stabilises the topoisomerase I–DNA
complex, preventing resealing of the DNA (Hsiang et al, 1985).
This leads to double-strand breaks, apoptosis and cell death.
Type II topoisomerases make transient breaks in double-
stranded DNA (dsDNA). Etoposide binds and stabilises an
intermediate enzyme–DNA structure inhibiting further enzyme
activity (Chen and Liu, 1994; Froelich-Ammon and Osheroff,
1995). When the cell attempts to replicate its DNA, these
complexes are disrupted causing double-strand breaks, which,
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Figure 2 Difference from target concentration. Graph demonstrating the variability of plasma etoposide concentrations, measured on days 2 and 4 of the
infusion, for each cycle.
Table 5 Patients requiring dose adjustments of etoposide phosphate
following measured etoposide levels more or less than 10% from the target
level
Cycle
number
No. of
patients
treated
No. of
patients for
whom data
available
Patients
requiring dose
adjustment on
day 2
Patients
requiring dose
adjustment on
day 4
12 1 2 1 1 8 4
22 1 1 9 1 5 8
31 8 1 8 1 2 8
41 4 1 3 6 6
51 4 1 4 1 2 4
61 2 1 2 7 7
Table 6 Response data for evaluable patients (X3 cycles of treatment)
Response to treatment
Dose level n PR SD PD
Platinum
resistant
Previous
paclitaxel
1a (1.0/2.0) 2 2 0 0 0 2
1b (0.85/2.0) 3 0 1 2 2 3
2a (0.85/1.0) 9 2 3 4 4 5
2b (0.85/1/5) 4 1 2 1 1 4
Total 18 5 6 7 7 14
PR¼partial remission; SD¼stable disease; PD¼progressive disease.
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Figure 3 European Organisation for Research and Treatment of Cancer
(EORTC) score. Mean EORTC QOL scores (71s.d.) calculated at
baseline, before cycles 3 and 6 and after cycle 6.
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sunless repaired, will be lethal to the cell. Thus, etoposide
cytotoxicity depends both on the level of topoisomerase II, which
is expressed only in dividing cells in the later phases of the cell
cycle (Heck et al, 1988), and secondly on duration of exposure of
cells to the drug.
The in vitro studies described here demonstrate the schedule
dependence underlying the interaction between topoisomerase I
and II inhibitors (SN-38 was used for in vitro experiments as it is
also a topoisomerase I inhibitor). These data also demonstrate
antagonism when the two agents were used simultaneously, where
the expected effect (20% apoptosis) based on the activity of each
agent used alone was not observed in any cell line. Increased
activity, inducing the greatest percentage of apoptotic cells, was
observed with schedules in which the two drugs were given
sequentially. The most active combination overall was SN-38 for 3
days, followed by 1 day without drug treatment, and then
etoposide for a further 3 days. Cell cycle data (not shown)
suggested that the increased apoptotic effect observed with
consecutive exposures may be due to relief of the cell cycle block
occurring after exposure to the first agent, when that agent is
removed and the cells are then exposed to the second agent. This is
more marked when the drug-free interval is short. These results led
to the adoption of a similar schedule for the clinical trial.
These results are in keeping with previous in vitro studies
demonstrating synergy when topotecan is followed by etoposide
(Bonner and Kozelsky, 1996; Grabowski and Ganapathi, 1996;
Chen et al, 2002). Synergy has also been demonstrated in human
xenograft mouse tumour models (Kim et al, 1992; Whitacre et al,
1997). Additive effects have also been observed when topoisome-
rase I and II inhibitors were given sequentially as opposed to
simultaneously (Bertrand et al, 1992). By contrast, simultaneous
incubation of cells with camptothecin (a topoisomerase I inhibitor)
and etoposide has shown reduced cytotoxicity compared to
etoposide given alone (Kaufmann, 1991).
The preclinical data presented here suggested synergistic activity
when cells are treated sequentially with topoisomerase I then II
inhibition. The topoisomerase ‘shutdown’ model predicts that
treatment of cells with a topoisomerase I inhibitor results in
upregulation of topoisomerase II levels, as an alternative DNA
repair mechanism is activated. Sequential treatment with a
topoisomerase II inhibitor, where the activity is in part dependent
on topoisomerase II levels is therefore predicted to be synergistic.
However, in a study in patients with advanced non-SCLC, of
topotecan 0.85mgm
 2day
 1 as a continuous i.v. infusion for 24h
followed by oral etoposide 100mg b.i.d. on days 7–9, only one
patient responded to treatment and the authors concluded that in
future studies etoposide should be given more closely following the
topotecan (Dowlati et al, 2001). Etoposide phosphate infusions
allow prolonged scheduling of etoposide with pharmacokinetic
monitoring to allow dose adjustments. Trials in our unit over the
past decade have shown this to be feasible and well tolerated
(O’Byrne et al, 1997; Joel et al, 1998; Braybrooke et al, 2003).
Experience from previous studies, together with the preclinical
data presented here, led to the adoption of the sequential
administration of topotecan for 5 days followed by EP for 5 days
as a novel regimen to be investigated in this phase I study in
patients with advanced ovarian cancer. As anticipated, the major
toxicity of topotecan followed by EP was myelosuppression. The
MTD was topotecan 0.85mgm
 2day
 1 followed immediately by
a 5-day infusion of EP at a plasma concentration of 1mgml
 1.
However, seven out of 11 patients on this dose level completed six
cycles, in keeping with this dose level being a feasible dose for
further study in a phase II trial. Two commonly used second-line
treatments for ovarian cancer are single agent topotecan
1.5mgm
 2day
 1 days 1–5 q21 and liposomal doxorubicin
50mgm
 2 q28. These schedules have been compared head to
head in a phase III study (Gordon et al, 2001). Table 7 compares
the toxicities observed in the Gordon study with those from this
study at the dose level suggested for phase II evaluation. The
haematological toxicities from this study and the single agent
topotecan arm are similar, especially given the use of stem cell
growth factor support in the Gordon study. This strengthens the
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scase further for the use of topotecan/EP as reasonable for a
palliative regimen.
The combination of topotecan followed by etoposide has been
evaluated in other studies. In patients with AML (acute myeloid
leukaemia), an MTD of topotecan 1.5mgm
 2day
 1 continuous
infusion days 1–5 followed by etoposide 100mgm
 2day
 1  3
was identified (Crump et al, 1999). Mucositis was the DLT with
grade 4 neutropenia and thrombocytopenia also observed. Other
disease-specific phase I studies of sequential topotecan and
etoposide have also found myelosuppression to be dose limiting
(Cooper et al, 1996; Herben et al, 1997; Hammond et al, 1998;
Crump et al, 2002). However, a phase I study in SCLC found
topotecan 0.75mgm
 2day
 1 followed by a 1-h infusion of
etoposide 60mgm
 2day
 1 daily for 5 days in a three weekly cycle
was well tolerated (O’Neill et al, 2001). Two studies have examined
the effect of order of sequential topotecan and etoposide in
patients with lung cancer. Patients received the two drugs in the
opposite order in subsequent cycles. No difference in toxicity was
observed between the different sequences and in both studies,
myelotoxicity was dose limiting (Huisman et al, 2001; Mok et al,
2002).
The response rate in this study was 28% in evaluable patients, of
whom half were resistant to platinum. This compares favourably
with the response rate of 20.5% for topotecan given second line
in advanced ovarian cancer (ten Bokkel Huinink et al, 1997). All
responding patients had been sensitive to platinum first line. Five
of the six responding patients had also been treated previously
with paclitaxel, supporting the data that the combination of
topotecan and etoposide is noncrossresistant with paclitaxel. Of
18 patients, 12 were evaluable by Ca125 and had a decrease or
stabilisation of their levels. Although this has not been shown to
correlate with activity, it may be that more minor improvements in
disease parameters are clinically relevant in the setting of advanced
disease, where prolonged stabilisation is a valid clinical objective.
The QOL data showed a trend to improvement during the course
of the study. Quality of life scores were statistically related to
haemoglobin concentration, as previously described (Littlewood
et al, 2001).
There are two human type II topoisomerases, a and b.
Topoisomerase IIa levels vary with the cell cycle (unlike
topoisomerase IIb) and are not detectable in S-phase but increase
through the cell cycle, peaking at G2/M (Woessner et al, 1991). An
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Figure 5 Topoisomerase IIa levels/arbitrary units. Topoisomerase IIa levels in peripheral blood. An example Western blot of topoisomerase IIa (A).
Lymphopreps were made from peripheral blood samples taken pretreatment (1), post-topotecan (2) and post-etoposide (3) administration. Western
blotting was performed on proteins from the lymphocyte cell pellet. Blots were probed with a monoclonal anti-topoisomerase IIa antibody. b Tubulin was
used as a loading control. Scatter graph of topoisomerase IIa levels in peripheral lymphocytes for all 10 patients at baseline, after topotecan and at the end of
treatment (B).
Table 7 Comparison of percentage of patients with grade 3/4 toxicities
with that of Gordon et al (2001)
Topotecan
(0.85mgm
2day
 1
days 1–5, EP
(1lgml
 1) days
6–10
Topotecan
(1.5mgm
2day
 1)
days 1–5 q21
Liposomal
doxorubicin
(50mgm
 2)
q28
Neutropenia
a 82 77 12
Anaemia 45 28 5
Thrombocytopenia 45 34 1
Plantar/palmer
erythema
00 2 3
Stomatitis 0 0.4 8
aGrowth factor support was used in the study of Gordon et al (2001).
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sin vitro study demonstrated that topoisomerase IIa levels could be
induced in colon cancer cell xenografts that had been exposed
to topotecan. However, if topotecan treatment was withdrawn for
5 days, the topoisomerase IIa level fell back to baseline (Whitacre
et al, 1997). This further supports that etoposide should
administered immediately follow topotecan, as in this study.
Topoisomerase IIa levels measured during this study did not
show any significant changes from baseline to the end of treatment
with topoisomerase I then II inhibition, although there was a trend
for topoisomerase IIa levels to fall following topotecan (Figure 5B).
However, the topoisomerase IIa were measured in circulating
lymphocytes, which are not undergoing cell division. Only cycling
cells are expected to have high levels of topoisomerase IIa and to
be sensitive to topotecan and this may account for our findings in
peripheral blood.
Topoisomerase IIa levels measured in the tumour cell lines
did rise following SN-38 and fell again following etoposide, as
predicted in the topoisomerase ‘shutdown’ model (data not
shown). Similar results have been demonstrated in CML K562
cells treated with topoisomerase I then II inhibitors (Chen et al,
2002). A rise in topoisomerase IIa has also been observed in
peripheral blast cells from leukaemia patients by day 3 of
treatment with topotecan, although levels returned to baseline by
day 5 (Crump et al, 1999). In another study in leukaemia patients
treated with topotecan then etoposide and mitoxantrone, a rise
in topoisomerase IIa post topotecan correlated with response to
treatment (Mainwaring et al, 2002). A further study using
fluorescence cytometry to measure nuclear topoisomerase IIa
levels in cells from patients with AML also showed a rise in the
median value after 48h of treatment with topotecan, falling again
by 5 days, although marked interpatient variability was observed
(Nicklee et al, 1996). Topoisomerase IIa levels have also been
measured in tumour biopsy specimens, pre and post topotecan
and etoposide treatment, in four patients as part of a phase I study.
There was no convincing pattern of change, in particular three out
of four patients’ levels were unchanged following topotecan
administration; however, these numbers are very small (Hammond
et al, 1998).
Separately, topotecan at 1.5mgm
 2day
 1 and EP at a plasma
etoposide concentration of 3mgml
 1, each over 5 days, can be
given with very manageable toxicity. In this study, substantially
lower doses of both topotecan and etoposide given sequentially
resulted in greater than anticipated haematological toxicity.
Furthermore, there was a higher tumour response rate (28% in
evaluable patients, 24% if all 21 patients were included) than would
be expected for the combination of drugs at these subtherapeutic
doses. Together with the preclinical data, the toxicity and response
rate from this study argue for synergy of action between these
drugs.
A shorter course of topotecan 1.5mgm
 2day
 1 for 3 days, q21
in platinum and paclitaxel-refractory ovarian cancer has been
investigated (Markman et al, 2000) and the 3-day topotecan
programme was found to be more convenient and less toxic than
the standard 5-day regimen with apparently comparable activity.
From this study, the recommended dose for a phase II trial is
topotecan 0.85mgm
 2day
 1 for 5 days followed immediately by
a 5-day infusion of EP at a plasma concentration of 1mgml
 1.
However, in view of the considerable haematological toxicity in
this study and the results from Markman’s study (Markman et al,
2000), a 3-day topotecan 0.85mgm
 2day
 1 schedule followed by a
5-day infusion of EP at 1mgml
 1 might be preferable. In future
studies, it would be of particular interest to measure topoisome-
rase IIa levels in cycling cells, either from tumour biopsy
specimens or in cells collected from patients with ascites.
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